Valuation: MediciNova, Inc.

Market Cap 8.12Cr 7.26Cr 6.77Cr 6.15Cr 12Cr 785.64Cr 12Cr 81Cr 32Cr 399.55Cr 30Cr 30Cr 1.28TCr P/E 2026 *
-6.47x
P/E 2027 * -3.69x
Enterprise Value 8.12Cr 7.26Cr 6.77Cr 6.15Cr 12Cr 785.64Cr 12Cr 81Cr 32Cr 399.55Cr 30Cr 30Cr 1.28TCr EV / Sales 2026 *
111x
EV / Sales 2027 * 244x
Free-Float
97.14%
Yield 2026 *
-
Yield 2027 * -
1 day-1.82%
1 week-3.28%
Current month-3.28%
1 month-7.43%
3 months+12.50%
6 months+14.08%
Current year+23.66%
1 week 1.6
Extreme 1.6
1.89
1 month 1.6
Extreme 1.6
3.9
Current year 1.22
Extreme 1.22
3.9
1 year 1.17
Extreme 1.168
3.9
3 years 1.12
Extreme 1.12
3.9
5 years 1.12
Extreme 1.12
4.65
10 years 1.12
Extreme 1.12
14.5
Manager TitleAgeSince
Chief Executive Officer 76 01/08/2005
Director of Finance/CFO 49 16/06/2022
Chief Tech/Sci/R&D Officer 60 01/09/2011
Director TitleAgeSince
Chairman 76 26/09/2000
Director/Board Member 60 24/07/2019
Director/Board Member 69 01/09/2004
Date Insider Type Main position Quantity % Market Cap. Importance
25/09/26
3D Investment Partners Pte. Ltd.
SellCompany -6,40,000 1.3003%
16/01/26 Free

Chief Technology Officer

3,50,000 0.7122%
16/01/26 Free

Chief Executive Officer

4,50,000 0.9156%
Change 5-day change 1-year change 3-year change Capi.($)
-1.82%-3.28%+29.08%-19.40% 8.12Cr
+4.16%+4.16%+49.37%+94.17% 7.47TCr
+0.46%-0.97%+23.51%+79.57% 5.88TCr
+0.17%+0.35%+6.85%+34.55% 4.84TCr
-0.47%-2.82%+328.34%+683.20% 4.28TCr
-0.60%-3.81%+28.76%+29.61% 4.28TCr
+0.17%-0.60%+6.48%+110.51% 4.12TCr
-0.11%+1.96%+9.19%+52.66% 3.11TCr
-2.07%+1.16%+35.00%+26.28% 3.03TCr
+0.33%-2.11%-9.27%-11.97% 2.4TCr
Average +0.00%-1.63%+50.73%+107.92% 3.94TCr
Weighted average by Cap. +0.60%-0.54%+56.02%+128.37%

Financials

2026 *2027 *
Net sales 7L 7L 6L 6L 10.41L 7.06Cr 10.49L 73.13L 28.57L 3.59Cr 27.41L 26.81L 12Cr 3L 3L 3L 3L 5L 3.22Cr 5L 33.39L 13.05L 1.64Cr 12.51L 12.24L 5.27Cr
Net income -1.29Cr -1.15Cr -1.07Cr -97.63L -1.84Cr -124.73Cr -1.85Cr -13Cr -5.05Cr -63Cr -4.84Cr -4.74Cr -203.92Cr -2.6Cr -2.32Cr -2.17Cr -1.97Cr -3.71Cr -251.33Cr -3.73Cr -26Cr -10Cr -127.82Cr -9.75Cr -9.54Cr -410.91Cr
Net Debt - -
Projected Income Statement - Annual - MediciNova, Inc.
Logo MediciNova, Inc.
MediciNova, Inc. is a biopharmaceutical company that is developing therapeutics with a primary focus on neurology, respiratory and liver diseases. The Company's development activities are focused on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (methamphetamine dependence, opioid dependence and alcohol dependence), prevention of acute respiratory distress syndrome, and Long COVID, and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease and hypertriglyceridemia. Its MN-166 (ibudilast) is a first-in-class, oral, anti-inflammatory and neuroprotective agent. The FDA has granted Fast Track designations to MN-166 (ibudilast) for three separate indications: progressive MS, ALS, and methamphetamine dependence.
Employees
6
Date Price Change Volume
08/26/08 $1.620 -1.82% 65,064
06/26/06 $1.650 -5.98% 1,20,405
05/26/05 $1.755 -1.40% 2,16,977
02/26/02 $1.780 +9.20% 2,75,013
01/26/01 $1.630 -2.69% 2,63,256
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - MediciNova, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.650USD
Average target price
8.250USD
Spread / Average Target
+400.00%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - MediciNova, Inc.
  1. Stock Market
  2. Stocks
  3. MNOV Stock